Headlines

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?

CEO Bruce Cozadd emphasized that Jazz remains “confident in its revenue guidance of $4.0 to $4.1 billion” for the full year.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *